Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class II · Moderate risk

Telmisartan Tablets

Failed Stability Specifications: Out of specification for blend uniformity.

Terminated Stability / shelf life Micro Labs Limited NDC 42571-227-30 D-0388-2024
Class III · Low risk

Lisinopril Tablets USP 20 mg

Presence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lots

Terminated Particulate / foreign matter NCS Healthcare of Kentucky Inc NDC 0615-7718-05 D-0114-2024
Class III · Low risk

Amlodipine Besylate Tablets

Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-721-03 D-0899-2023
Class II · Moderate risk

Metoprolol Succinate Extended-Release Tablets

Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.

Terminated Dissolution failure Amerisource Health Services LLC NDC 68001-501-00 D-0269-2023
Class I · High risk

Atenolol Tablets

Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets

Terminated Labeling / mix-up Golden State Medical Supply Inc. NDC 60429-027-10 D-0019-2023
Class II · Moderate risk

Irbesartan Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk

Irbesartan Tablets

Failed dissolution specifications.

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-841-13 D-1306-2022
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-842-13 D-1305-2022